Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

1.

A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia.

Zong HT, Peng XX, Yang CC, Zhang Y.

Asian J Androl. 2011 Nov;13(6):812-8. doi: 10.1038/aja.2011.86. Epub 2011 Sep 5. Review.

PMID:
21892196
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis.

Cindolo L, Fanizza C, Romero M, Pirozzi L, Autorino R, Berardinelli F, Schips L.

World J Urol. 2013 Jun;31(3):665-71. doi: 10.1007/s00345-012-1000-4. Epub 2012 Dec 14.

PMID:
23239103
[PubMed - indexed for MEDLINE]
3.
4.

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.

Bartsch G, Rittmaster RS, Klocker H.

World J Urol. 2002 Apr;19(6):413-25. Review.

PMID:
12022710
[PubMed - indexed for MEDLINE]
5.

Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS.

Cindolo L, Berardinelli F, Fanizza C, Romero M, Pirozzi L, Tamburro FR, Pellegrini F, Neri F, Pitrelli A, Schips L.

Arch Ital Urol Androl. 2013 Dec 31;85(4):200-6. doi: 10.4081/aiua.2013.4.200.

PMID:
24399122
[PubMed - indexed for MEDLINE]
6.

Transurethral resection of prostate and the role of pharmacological treatment with dutasteride in decreasing surgical blood loss.

Pastore AL, Mariani S, Barrese F, Palleschi G, Valentini AM, Pacini L, Petrozza V, Carbone A, Cappa M.

J Endourol. 2013 Jan;27(1):68-70. doi: 10.1089/end.2012.0231. Epub 2012 Oct 3.

PMID:
23030716
[PubMed - indexed for MEDLINE]
7.

Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).

Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS.

BJU Int. 2011 Aug;108(3):388-94. doi: 10.1111/j.1464-410X.2011.10195.x. Epub 2011 Jun 1.

PMID:
21631695
[PubMed - indexed for MEDLINE]
8.

[Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].

Arena F.

Minerva Urol Nefrol. 2013 Sep;65(3):211-6. Italian.

PMID:
23872632
[PubMed - indexed for MEDLINE]
9.

Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.

Dolder CR.

Ann Pharmacother. 2006 Apr;40(4):658-65. Epub 2006 Mar 28. Review.

PMID:
16569804
[PubMed - indexed for MEDLINE]
10.

Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia.

Djavan B, Milani S, Fong YK.

Expert Opin Pharmacother. 2005 Feb;6(2):311-7. Review. Erratum in: Expert Opin Pharmacother. 2005 Apr;6(4):681.

PMID:
15757426
[PubMed - indexed for MEDLINE]
11.

Current status of 5alpha-reductase inhibitors in the treatment of benign hyperplasia of prostate.

Kumar VL, Wahane VD.

Indian J Med Sci. 2008 Apr;62(4):167-75. Review.

PMID:
18445985
[PubMed - indexed for MEDLINE]
Free Article
12.

Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride.

Hahn RG, Fagerström T, Tammela TL, Van Vierssen Trip O, Beisland HO, Duggan A, Morrill B.

BJU Int. 2007 Mar;99(3):587-94.

PMID:
17407516
[PubMed - indexed for MEDLINE]
13.

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.

Bartsch G, Rittmaster RS, Klocker H.

Eur Urol. 2000 Apr;37(4):367-80. Review.

PMID:
10765065
[PubMed - indexed for MEDLINE]
14.

Dutasteride for the treatment of benign prostatic hyperplasia.

Wu C, Kapoor A.

Expert Opin Pharmacother. 2013 Jul;14(10):1399-408. doi: 10.1517/14656566.2013.797965. Review.

PMID:
23750593
[PubMed - indexed for MEDLINE]
15.

Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate.

Tuncel A, Ener K, Han O, Nalcacioglu V, Aydin O, Seckin S, Atan A.

Scand J Urol Nephrol. 2009;43(5):377-82. doi: 10.3109/00365590903164498.

PMID:
19921983
[PubMed - indexed for MEDLINE]
16.

Comparative effect of finasteride and dutasteride on chromogranin A levels.

Sciarra A, Salciccia S, Nesi G, Cattarino S, Alfarone A, Gentilucci A, Gentile V.

Anticancer Res. 2010 Nov;30(11):4737-42.

PMID:
21115933
[PubMed - indexed for MEDLINE]
17.

Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.

Schmidt LJ, Tindall DJ.

J Steroid Biochem Mol Biol. 2011 May;125(1-2):32-8. doi: 10.1016/j.jsbmb.2010.09.003. Epub 2010 Sep 29. Review.

PMID:
20883781
[PubMed - indexed for MEDLINE]
18.

The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis.

Cui Y, Zong H, Yang C, Yan H, Zhang Y.

Int Urol Nephrol. 2013 Aug;45(4):979-87. doi: 10.1007/s11255-013-0477-0. Epub 2013 Jun 1. Review.

PMID:
23728850
[PubMed - indexed for MEDLINE]
19.

Dutasteride for the treatment of prostate-related conditions.

Slater S, Dumas C, Bubley G.

Expert Opin Drug Saf. 2012 Mar;11(2):325-30. doi: 10.1517/14740338.2012.658040. Epub 2012 Feb 8. Review.

PMID:
22316171
[PubMed - indexed for MEDLINE]
20.

Finasteride for benign prostatic hyperplasia.

Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ.

Cochrane Database Syst Rev. 2010 Oct 6;(10):CD006015. doi: 10.1002/14651858.CD006015.pub3. Review.

PMID:
20927745
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk